Both semaglutide and tirzepatide represent significant advancements in diabetes management, offering tailored treatment options for patients striving to achieve better glycemic control and overall health
Fatal outcomes documented : First fatal case at therapeutic doses in a woman with intrahepatic cholestasis
It must be prescribed by a licensed doctor following a medical assessment
A thorough discussion with a medical professional will confirm if any aspect of your health history makes this treatment inappropriate for you
Risk of Upper Gastrointestinal Injury and Events in Patients Treated with Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature
In addition to these most popular options, other medications are available, but they require daily injections, making them less convenient than semaglutide